Metastatic prostate cancer can be treated with hormone-blocking medications that suppress testosterone production. While the use of one drug used to be the standard of care, guidelines now recommend physicians use a combination of two drugs that block hormones in different ways, according to a Feb. 18 news release from the National Cancer Institute.
Of physicians who did not prescribe two hormone-blocking drugs, 60% did so out of concern that the combination therapy would have too many side effects. Clinical trials have shown that patients who receive the combination therapy have a higher quality of life than those who don’t, according to the NCI release.
“One drug alone is no longer sufficient,” study author and oncologist at Salt Lake City-based University of Utah’s Huntsman Cancer Institute, Neeraj Agarwal, MD, said in the release. “Combining two [or more] really improves survival without compromising quality of life. But, if you look at the implementation of this data in the real world, we see a real disconnect.”
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
